Report on the International Colloquium on Cardio-Oncology (Rome, 12-14 March 2014)

Ewer, Michael; Gianni, Luca; Pane, Fabrizio; Sandri, Maria Teresa; Steiner, Rudolf K.; Wojnowski, Leszek; Yeh, Edward T.; Carver, Joseph R.; Lipshultz, Steven E.; Minotti, Giorgio; Armstrong, Gregory T.; Cardinale, Daniela; Colan, Steven D.; Darby, Sarah C.; Force, Thomas L.; Kremer, Leontien C. M.; Lenihan, Daniel J.; Sallan, Stephen E.; Sawyer, Douglas B.; Suter, Thomas M.
June 2014
Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1
Academic Journal
Cardio-oncology is a relatively new discipline that focuses on the cardiovascular sequelae of anti-tumour drugs. As any other young adolescent discipline, cardio-oncology struggles to define its scientific boundaries and to identify best standards of care for cancer patients or survivors at risk of cardiovascular events. The International Colloquium on Cardio-Oncology was held in Rome, Italy, 12-14 March 2014, with the aim of illuminating controversial issues and unmet needs in modern cardio-oncology. This colloquium embraced contributions from different kind of disciplines (oncology and cardiology but also paediatrics, geriatrics, genetics, and translational research); in fact, cardio-oncology goes way beyond the merging of cardiology with oncology. Moreover, the colloquium programme did not review cardiovascular toxicity from one drug or the other, rather it looked at patients as we see them in their fight against cancer and eventually returning to everyday life. This represents the melting pot in which anti-cancer therapies, genetic backgrounds, and risk factors conspire in producing cardiovascular sequelae, and this calls for screening programmes and well-designed platforms of collaboration between one key professional figure and another. The International Colloquium on Cardio-Oncology was promoted by the Menarini International Foundation and co-chaired by Giorgio Minotti (Rome), Joseph R Carver (Philadelphia, Pennsylvania, United States), and Steven E Lipshultz (Detroit, Michigan, United States). The programme was split into five sessions of broad investigational and clinical relevance (what is cardiotoxicity?, cardiotoxicity in children, adolescents, and young adults, cardiotoxicity in adults, cardiotoxicity in special populations, and the future of cardio-oncology). Here, the colloquium chairs and all the session chairs briefly summarised what was said at the colloquium. Topics and controversies were reported on behalf of all members of the working group of the International Colloquium on Cardio-Oncology.


Related Articles

  • Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group. Icli, F; Akbulut, H; Uner, A; Yalcin, B; Baltali, E; Altinbas, M; Coskun, S; Komurcu, S; Erkisi, M; Demirkazik, A; Senler, F C; Sencan, O; Büyükcelik, A; Boruban, C; Onur, H; Zengin, N; Sak, S D // British Journal of Cancer;2/28/2005, Vol. 92 Issue 4, p639 

    Our objective was to determine whether oral etoposide and cisplatin combination (EoP) is superior to paclitaxel in the treatment of advanced breast cancer (ABC) patients pretreated with anthracyclines. From December 1997 to August 2003, 201 patients were randomised, 100 to EoP and 101 to...

  • Anthracyclines/antineoplastics/immunosuppressants.  // Reactions Weekly;6/24/2006, Issue 1107, p6 

    The article discusses the case studies of five patients who developed translocation carcinomas of the kidney after chemotherapy in childhood. It references a study by P. Argani et al, published in the April 2006 issue of the "Journal of Clinical Oncology." Background information on the each...

  • A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Ford, Hugo; Yoon-Sim Yap; Miles, David; Makris, Andreas; Hall, Marcia; Miller, Liz; Harries, Mark; Smith, Ian; Johnston, Stephen // Cancer Chemotherapy & Pharmacology;Dec2006, Vol. 58 Issue 6, p809 

    Background: Docetaxel has significant activity in metastatic breast cancer and weekly schedules are associated with less myelosuppression than 3-weekly schedules. We evaluated the toxicity and the activity of weekly docetaxel in anthracycline-pretreated patients. Patients and methods: A total of...

  • Caffeine enhances myocardial uptake of idarubicin but reverses its negative inotropic effect. Kang, Wonku; Weiss, Michael // Naunyn-Schmiedeberg's Archives of Pharmacology;Feb2003, Vol. 367 Issue 2, p151 

    Idarubicin (IDA) is a member of an important class of anticancer agents, the anthracycline antibiotics. Although the clinical efficacy of anthracyclines is limited by a high incidence of severe cardiac toxicity, our understanding of IDA transport into the heart is still limited. In a previous...

  • Adverse drug reactions and therapeutic errors in older adults: A hazard factor analysis of poison center data. Cobaugh, Daniel J.; Krenzelok, Edward P. // American Journal of Health-System Pharmacy;11/15/2006, Vol. 63 Issue 22, p2228 

    Purpose. The severity of hazards posed by medications implicated in poisoning in older adults was characterized. Methods. Toxic Exposure Surveillance System (TESS) cases from 1993 through 2002 involving a single substance in patients age 60 years or older and coded as an ad- verse drug reaction...

  • Cardiomiopatía inducida por antraciclinas en pacientes tratadas por cáncer de mama. Alarcón, Liliana; Esper, Jhonatan; Álzate, Fabián; Insuasty E., Jesús S. // Revista Médicas UIS;2012, Vol. 25 Issue 3, p265 

    Anthracyclines are chemotherapeutic agents that were considered the cornerstone for multiple chemotherapy regimes. Despite being an encouraging treatment, it faces several side-effects, some of the more prominent are heart condition characterized by arrhythmogenic, cardiac ischemic events,...

  • Doxorubicin induces senescence and impairs function of human cardiac progenitor cells. Piegari, Elena; Angelis, Antonella; Cappetta, Donato; Russo, Rosa; Esposito, Grazia; Costantino, Sarah; Graiani, Gallia; Frati, Caterina; Prezioso, Lucia; Berrino, Liberato; Urbanek, Konrad; Quaini, Federico; Rossi, Francesco // Basic Research in Cardiology;Mar2013, Vol. 108 Issue 2, p1 

    The increasing population of cancer survivors faces considerable morbidity and mortality due to late effects of the antineoplastic therapy. Cardiotoxicity is a major limiting factor of therapy with doxorubicin (DOXO), the most effective anthracycline, and is characterized by a dilated...

  • Optimizing Patient Care: Minimizing the Impact of Chemotherapy-Induced Toxicities.  // ONS News;Sep2004 Supplement, Vol. 19, p11 

    The article discusses the ways that oncology nurses can minimize the impact of chemotherapy-induced toxicities in cancer patients. It is stated that the research on reducing the side effects of anthracyclines and optimizing patient care and quality of life is constantly evolving. It highlights...

  • Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Ishida, Takanori; Kiba, Takayoshi; Takeda, Motohiro; Matsuyama, Kotone; Teramukai, Satoshi; Ishiwata, Ryota; Masuda, Norikazu; Takatsuka, Yuichi; Noguchi, Shinzaburo; Ishioka, Chikashi; Fukushima, Masanori; Ohuchi, Noriaki // Cancer Chemotherapy & Pharmacology;Jul2009, Vol. 64 Issue 2, p361 

    The purpose of this study was to investigate the activity of capecitabine and trastuzumab in patients with HER2-overexpressing metastatic breast caner resistant to both anthracyclines and taxanes. From June 2003 and May 2006, 40 female patients with measurable or assessable metastatic breast...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics